15-min delayed · Sep 10, 2:30 PM ET · Get real-time quotes →
The Quantellect read.Of the 22 firms covering Regeneron Pharmaceuticals Inc, 15 rate it Buy or better, 7 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $185.00 to $1030.00 (about 5.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $779.80 sits 2% below the current $797.62. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $15.61 next quarter toward $50.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 ratings
Moderate Buy
Strong Buy00%
Buy1568%
Hold732%
Sell00%
Strong Sell00%
Based on 22 analysts giving stock ratings to Regeneron Pharmaceuticals Inc.
As of Sep, 15 of 22 firms rate REGN a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
REGN EPS & revenue forecast
EPS · NEXT QUARTER
$15.61
Range $10.47 – $18.62 · 21 analysts · +36% YoY
Next period, 21 analysts expect Regeneron Pharmaceuticals Inc to earn $15.61 a share (range $10.47 – $18.62), versus $11.44 a year earlier. Full-year consensus is $53.55, growing to $50.38 the year after.
REVENUE · NEXT QUARTER
$4.6B
Range $4.0B – $4.9B · 21 analysts · +19% YoY
Revenue is expected to reach $4.6B (range $4.0B – $4.9B), +19.2% year-over-year. Full-year consensus is $16.9B, rising to $18.4B next year.
Top analysts covering Regeneron Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on REGN.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$1000.00+25.4% to target
Overall win rate
53%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #121
Hold
$641.00-19.6% to target
Overall win rate
56%
+ Follow
#3
Matthew Harrison
Morgan Stanley · Rank #300
Hold
$758.00-5.0% to target
Overall win rate
45%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$891.00+11.7% to target
Overall win rate
47%
+ Follow
#5
RW
Robert Wasserman
Benchmark · Rank #336
Buy
$185.00-76.8% to target
Overall win rate
39%
+ Follow
REGN stock forecast FAQ
What is REGN's average 12-month price target?+
The 15 analysts with a live target average $779.80 for Regeneron Pharmaceuticals Inc over the next 12 months, ranging from a $1030.00 high to a $185.00 low.
Is REGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 22 analyst ratings, 15 are Buy or Strong Buy, 7 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for REGN?+
The Street-high target is $1030.00 (Guggenheim), and the Street-low is $185.00 (Benchmark). The average of all 15 active targets is $779.80.
How many Wall Street analysts cover REGN?+
22 analysts have an active rating on Regeneron Pharmaceuticals Inc, and 15 firms carry a live 12-month price target.
Who is the most accurate analyst covering REGN?+
Among analysts who currently cover REGN, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $1000.00 target.
What is Regeneron Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $15.61 per share (range $10.47 – $18.62) across 21 analysts. Full-year EPS is projected at $53.55, rising to $50.38 the following year.
How much revenue is Regeneron Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $4.6B (range $4.0B – $4.9B). Full-year revenue is projected at $16.9B, growing to $18.4B next year.
Have analysts been upgrading or downgrading REGN lately?+
As of Sep, 15 of 22 firms rate REGN a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their REGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
